| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
depreciation and amortization, operating profit, interest expense,
and income tax (expense) benefit for the three months and nine
months ended August 31, 2017:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended August 31,
2017 |
|
|
For the nine months
ended August 31, 2017 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,780,565 |
|
|
$ |
18,567,285 |
|
|
Prepacyte®-CB
|
|
|
115,376 |
|
|
|
342,031 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
6,895,941 |
|
|
$ |
18,909,316 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,771,403 |
|
|
$ |
4,681,276 |
|
|
Prepacyte®-CB
|
|
|
206,072 |
|
|
|
404,262 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,977,475 |
|
|
$ |
5,085,538 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
24,295 |
|
|
$ |
69,734 |
|
|
Prepacyte®-CB
|
|
|
9,064 |
|
|
|
27,191 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
33,359 |
|
|
$ |
96,925 |
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,552,168 |
|
|
$ |
3,850,206 |
|
|
Prepacyte®-CB
|
|
|
(99,935 |
) |
|
|
(89,597 |
) |
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
1,452,233 |
|
|
$ |
3,760,609 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
314,890 |
|
|
$ |
937,248 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
314,890 |
|
|
$ |
937,248 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(490,558 |
) |
|
$ |
(1,128,012 |
) |
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax expense
|
|
$ |
(490,558 |
) |
|
$ |
(1,128,012 |
) |
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of
August 31, 2017 and November 30, 2016:
|
|
|
|
|
|
|
|
|
| |
|
As of August 31, 2017 |
|
|
As of November 30,
2016
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
20,761,483 |
|
|
$ |
18,960,261 |
|
|
Prepacyte®-CB
|
|
|
555,328 |
|
|
|
578,207 |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
21,316,811 |
|
|
$ |
19,538,468 |
|
|
|
|
|
|
|
|
|
|
The following table shows, by segment: net revenue, cost of sales,
depreciation and amortization, operating profit, interest expense,
and income tax (expense) benefit for the three months and nine
months ended August 31, 2016:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended August 31,
2016 |
|
|
For the nine months
ended August 31, 2016 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,243,803 |
|
|
$ |
16,970,939 |
|
|
Prepacyte®-CB
|
|
|
88,135 |
|
|
|
286,253 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
6,331,938 |
|
|
$ |
17,257,192 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,482,900 |
|
|
$ |
4,073,293 |
|
|
Prepacyte®-CB
|
|
|
68,331 |
|
|
|
257,329 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,551,231 |
|
|
$ |
4,330,622 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
27,310 |
|
|
$ |
84,542 |
|
|
Prepacyte®-CB
|
|
|
12,436 |
|
|
|
38,624 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
39,746 |
|
|
$ |
123,166 |
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
808,254 |
|
|
$ |
1,864,325 |
|
|
Prepacyte®-CB
|
|
|
(1,870,329 |
) |
|
|
(1,887,594 |
) |
|
|
|
|
|
|
|
|
|
|
Total operating loss
|
|
$ |
(1,062,075 |
) |
|
$ |
(23,269 |
) |
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
199,439 |
|
|
$ |
781,971 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
22,265 |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
199,439 |
|
|
$ |
804,236 |
|
|
|
|
|
|
|
|
|
|
|
Income tax benefit
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
898,838 |
|
|
$ |
697,103 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax benefit
|
|
$ |
898,838 |
|
|
$ |
697,103 |
|
|
|
|
|
|
|
|
|
|
|